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RESEARCH ARTICLE
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Abstract
Breast cancer is the most common solid organ malignancy and the most frequent cause of
cancer death among women worldwide. Previous research has yielded insights into its
genetic etiology, but there remains a gap in the understanding of genetic factors that contrib-
ute to risk, and particularly in the biological mechanisms by which genetic variation modu-
lates risk. The National Cancer Institute’s “Up for a Challenge” (U4C) competition provided
an opportunity to further elucidate the genetic basis of the disease. Our group leveraged the
seven datasets made available by the U4C organizers and data from the publicly available
UK Biobank cohort to examine associations between imputed gene expression and breast
cancer risk. In particular, we used reference datasets describing the breast tissue and whole
blood transcriptomes to impute expression levels in breast cancer cases and controls. In
trans-ethnic meta-analyses of U4C and UK Biobank data, we found significant associations
between breast cancer risk and the expression of RCCD1 (joint p-value: 3.6x10-06) and
DHODH (p-value: 7.1x10-06) in breast tissue, as well as a suggestive association for
ANKLE1 (p-value: 9.3x10-05). Expression of RCCD1 in whole blood was also suggestively
associated with disease risk (p-value: 1.2x10-05), as were expression of ACAP1 (p-value:
1.9x10-05) and LRRC25 (p-value: 5.2x10-05). While genome-wide association studies
(GWAS) have implicated RCCD1 and ANKLE1 in breast cancer risk, they have not identified
the remaining three genes. Among the genetic variants that contributed to the predicted
expression of the five genes, we found 23 nominally (p-value < 0.05) associated with breast
cancer risk, among which 15 are not in high linkage disequilibrium with risk variants previ-
ously identified by GWAS. In summary, we used a transcriptome-based approach to in-
vestigate the genetic underpinnings of breast carcinogenesis. This approach provided an
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Author summary
There is a clear genetic basis of breast cancer, and previous work has identified numerous
genetic variants that increase risk of this common disease. However, much of the underly-
ing genetic variation in breast cancer remains unexplained. To address this void, as part of
the National Cancer Institute’s “Up for a Challenge” (U4C) competition, we undertook a
large-scale study of genetically regulated gene expression and breast cancer. Specifically,
we estimated gene expression levels based on germline genetics for subjects in the seven
breast cancer studies provided by U4C and for subjects in the UK Biobank. We then eval-
uated associations between gene expression and breast cancer and detected three novel
and two known breast cancer genes. These genes exhibit potential biological mechanisms
for impacting breast carcinogenesis. Our work highlights the value of leveraging different
sources of data to more thoroughly study the genetic basis of complex diseases.
Introduction
Breast cancer is the most common solid organ malignancy and the most frequent cause of can-
cer death among women worldwide [1]. Family history is among the strongest known risk fac-
tors for breast cancer. Individuals with a first-degree relative affected by the disease have a
roughly two-fold increased risk of developing breast cancer themselves, and a more extensive
family history or having relatives diagnosed at an earlier age confers yet greater risk [2–4]. A
recent twin study estimated the heritability of breast cancer to be 31% [5], but the combination
of rare variants (e.g., in BRCA1, BRCA2) identified from linkage studies (summarized in [6])
and common single nucleotide polymorphisms (SNPs) at roughly 100 loci identified from
genome-wide association studies (GWAS; summarized in [7]) explain only one-third of the
excess familial risk of disease [8]. Thus, a substantial gap remains in the understanding of the
genetic factors that contribute to breast cancer risk.
The National Cancer Institute’s Up for a Challenge (U4C) competition offered a unique
opportunity to further elucidate the genetic basis of breast cancer. Seven ethnically diverse
GWAS datasets were made available in dbGaP and participants were challenged to use innova-
tive approaches to identify novel loci, genes, and/or genomic features involved in breast cancer
susceptibility. Our group leveraged the U4C genotype data along with gene expression datasets
to search for evidence of additional genes involved in breast cancer susceptibility.
Recently, methods have been developed to leverage genotypic data toward imputing gene
expression that can then be evaluated in association studies [9]. These methods are based on
strong evidence that expression quantitative trait loci (eQTLs), which contribute to regulating
gene expression levels, account for a substantial portion of the risk of various disease pheno-
types [10–12]. A reference dataset with genotype and gene expression data is used to derive a
set of SNPs that optimally predicts the expression of each gene. These SNPs can then be used
to impute genetically regulated gene expression in datasets without measured expression data,
and these imputed values can then be tested for associations with a phenotype of interest. Eval-
uating gene expression with respect to breast cancer risk has the potential to offer insights dis-
tinct from those available from traditional GWAS. First, associations with gene expression
Cis-eQTLs and breast cancer risk
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have clear functional interpretations. In contrast, the functional relevance of SNPs discovered
by GWAS usually remains unclear. Second, association testing for genes substantially reduces
the multiple testing burden relative to single variant approaches. Third, association testing for
gene expression allows for rational combination of multiple SNPs, which may help to enhance
weak signals.
We conducted a transcriptome-wide association study of gene expression and breast cancer
risk by applying an innovative method called PrediXcan [9] that uses eQTL reference tran-
scriptome datasets to impute genetically regulated expression. We used reference expression
data from breast tissue and whole blood to identify the SNPs that predict gene expression. We
then used the U4C datasets combined with data from the UK Biobank to search for genes for
which predicted expression is associated with susceptibility to breast cancer. The approach
provided an avenue for deciphering the functional relevance of both genes and SNPs involved
in breast cancer development.
Results
Transcriptome-wide imputation in U4C and UK Biobank data
After splitting the GWAS of Breast Cancer in the African Diaspora (African Diaspora), Breast
and Prostate Cancer Cohort Consortium GWAS (BPC3), and Multiethnic Cohort GWAS in
African Americans, Latinos, and Japanese (MEC) datasets into sub-populations, and excluding
the Nurses’ Health Study (NHS2) sub-population from the BPC3 (because it was already
included in the Cancer Genetic Markers of Susceptibility Breast Cancer GWAS [CGEMS]
dataset), we imputed gene expression into 14 separate discovery studies with a total of 12,079
breast cancer cases and 11,442 controls. In addition, we used 3,370 cases and 19,717 controls
from the publicly available UK Biobank cohort study as a replication population [13]. Addi-
tional details of the study populations, genotyping, and quality control (QC) process are pro-
vided in Table 1 and the Materials and Methods section.
The developers of PrediXcan previously determined the cis-eQTL SNPs relevant to the esti-
mation of gene expression in 44 distinct tissue types. The weights that should be applied to
each SNP to impute transcript levels in other datasets are maintained in the publicly available
database PredictDB. For our study, we elected to use the weights developed based on gene
expression in breast tissue and, separately, in whole blood. We used the former for its direct
relevance to breast cancer (developed based on n = 173 samples) and the latter because the
weights were developed based on the largest number of samples among all tissues (n = 922).
Weights for the prediction of breast tissue expression were available for 4,473 genes based
on 102,762 unique SNPs. The mean expected correlation between imputed transcript levels
and true gene expression across all transcripts was 0.097. Regarding the prediction of whole
blood expression, weights were available for 9,791 genes based on 249,696 unique SNPs. The
mean expected correlation between imputed transcript levels and true gene expression across
all transcripts was 0.145.
Transcriptome-wide associations with breast cancer risk
A meta-analysis of the U4C discovery datasets yielded 280 transcripts with imputed breast tis-
sue levels nominally (p-value< 0.05) associated with breast cancer risk (S1A Table). We eval-
uated all of these genes for associations in the UK Biobank data. Our genomic inflation factor
was 1.07 (λ1000 = 1.01). All genes with a p-value< 0.10 in this replication cohort and effect esti-
mates in the same direction as the discovery effect were included in a combined meta-analysis
of discovery and replication. Table 2 describes the three genes for which the combined meta-
analysis showed evidence of an association with breast cancer. Decreased expression levels of
Cis-eQTLs and breast cancer risk
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RCCD1 (p-value: 3.6x10-06) and DHODH (p-value: 7.1x10-06) showed significant associations
with breast cancer risk based on a Bonferroni-corrected significance threshold (0.05 / 4,473 =
1.1x10-05), and higher expression levels of ANKLE1 demonstrated a suggestive association
Table 1. Characteristics of the Up for a Challenge datasets (discovery) and the UK Biobank (replication).
Dataset (Source Dataset) Race / Ethnicity # Casesa # Controlsa Genotyping Platform
Discovery
AABC (AABC) African 2,755 2,461 Illumina Human1M-Duo BeadChip
African (African Diaspora) African 699 606 Illumina HumanOmni2.5-Quad
African American / Barbadian (African Diaspora) African 934 1,400 Illumina HumanOmni2.5-Quad
CGEMS (CGEMS) European 1,125 1,126 Illumina HumanHap550
CPSII (BPC3) European 289 292 HumanHap550; HumanHap 660
EPIC (BPC3) European 501 491 HumanHap550; HumanHap 660
Latina Admixture (Latina Admixture) Latina 800 365 Affymetrix GWAS SNP Array 6.0
MEC–European (BPC3) European 85 98 HumanHap550; HumanHap 660
MEC–Japanese (MEC) East Asian 885 822 Human660W; Human-1M
MEC–Latina (MEC) Latina 520 544 Human660W; Human-1M
NHS2 (BPC3) European 71 372 HumanHap550; HumanHap 660
PBCS (BPC3) European 532 495 HumanHap550; HumanHap 660
PLCO (BPC3) European 252 337 HumanHap550; HumanHap 660
Shanghai (Shanghai) East Asian 2,631 2,033 Affymetrix GWAS SNP Array 6.0
Replication
UK Biobank European 3,370 19,717 UK BiLEVE Axiom; UK Biobank Axiom
Abbreviations: AABC: African American Breast Cancer GWAS; African Diaspora: GWAS of Breast Cancer in the African Diaspora; BPC3: Breast and
Prostate Cancer Cohort Consortium GWAS; CGEMS: Cancer Genetic Markers of Susceptibility Breast Cancer GWAS; CPSII: Cancer Prevention Study II;
EPIC: European Prospective Investigation into Cancer and Nutrition; GWAS: genome-wide association study; Latina Admixture: San Francisco Bay Area
Latina Breast Cancer Study; MEC: Multiethnic Cohort GWAS in African Americans, Latinos, and Japanese; NHS2: Nurses’ Health Study 2; PBCS: Polish
Breast Cancer Study; PLCO: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; Shanghai: Shanghai Breast Cancer Genetics Study; SNP:
single nucleotide polymorphism
a After all quality control steps
https://doi.org/10.1371/journal.pgen.1006690.t001
Table 2. Effect estimates and standard errors for gene expression suggestively (p-value < 1.0x10-04) associated with breast cancer risk in a meta-
analysis of the Up for a Challenge and UK Biobank datasets.
# SNPs in Imputation U4C UK Biobank Meta-analysis
Gene Locationa Prediction Qualityb Beta (SE) p-value Beta (SE) p-value Beta (SE) p-value
Breast Tissue Gene
Expression
RCCD1 15q26.1 24 0.16 -0.11 (0.038) 5.8x10-03 -0.24 (0.057) 2.6x10-05 -0.15 (0.032) 3.6x10-06
DHODH 16q22.2 7 0.026 -0.52 (0.12) 2.4x10-05 -0.29 (0.15) 0.056 -0.43 (0.095) 7.1x10-06
ANKLE1 19p13.11 6 0.081 0.19 (0.093) 0.044 0.43 (0.12) 1.9x10-04 0.28 (0.072) 9.3x10-05
Whole Blood Gene
Expression
RCCD1 15q26.1 20 0.35 -0.074 (0.026) 4.7x10-03 -0.14 (0.039) 2.7x10-04 -0.095 (0.022) 1.2x10-05
ACAP1 17p13.1 19 0.39 0.098 (0.037) 7.9x10-03 0.11 (0.033) 7.9x10-04 0.11 (0.025) 1.9x10-05
LRRC25 19p13.11 33 0.35 0.086 (0.029) 2.7x10-03 0.094 (0.034) 6.5x10-03 0.089 (0.022) 5.2x10-05
Abbreviations: SE: standard error; SNP: single nucleotide polymorphism; U4C: Up for a Challenge
a According to human reference genome GRCh37/hg19
b r2 estimate derived from 10 fold cross-validation of true gene expression and predicted gene expression
https://doi.org/10.1371/journal.pgen.1006690.t002
Cis-eQTLs and breast cancer risk
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(p-value: 9.3x10-05). The DHODH association was largely driven by the discovery dataset (p-
value: 2.4x10-05) with little contribution from replication (p-value: 0.056). Estimates from each
of the discovery datasets and the replication dataset are presented in S1 Fig for each of the
three genes. While RCCD1 and ANKLE1 have been implicated by GWAS of breast cancer risk,
DHODH has not been previously identified.
The imputed expression of genes based on whole blood yielded no statistically significant
associations with breast cancer risk after multiple testing correction (Bonferroni significance
threshold = 0.05 / 9,791 = 5.1x10-06) (S1B Table). Our genomic inflation factor was 1.06
(λ1000 = 1.01). However, Table 2 shows results for three genes that showed suggestive evidence
of an association (p-value< 1.0x10-04). Notably, decreased expression levels of RCCD1 in
whole blood (as in breast tissue) were suggestively associated with breast cancer risk (p-value:
1.2x10-05). Furthermore, we found that higher expression levels of ACAP1 (p-value: 1.9x10-05)
and LRRC25 (p-value: 5.2x10-05) were suggestively associated with an increased risk of breast
cancer. Estimates from each of the discovery datasets and the replication dataset are presented
in S2 Fig for each of the three genes. Neither ACAP1 nor LRRC25 have previously been impli-
cated by GWAS of breast cancer risk.
The volcano plots in S3 Fig depict the U4C and UK Biobank meta-analysis summary statis-
tics for 4,469 breast tissue transcripts and 9,768 whole blood transcripts. Outliers with beta
estimates outside three standard deviations from the mean were excluded from the plots–four
for breast tissue and 23 for whole blood. The x-axis gives the beta effect sizes reflecting the fold
change in gene expression between cases and controls, and the y-axis plots the corresponding
-log10(p-value). S3 Fig is thus illustrative of the differential expression between cases and con-
trols for genes across the transcriptome. For breast tissue expression (S3A Fig), we saw few
genes beyond those noted above showing any evidence of association. In contrast, the distribu-
tion of p-values for whole blood expression (S3B Fig) was slightly broader, albeit with a more
stringent threshold for statistical significance. However, among those genes significantly or
suggestively associated with breast cancer risk, the magnitudes of the effect sizes were larger
for breast tissue expression (|Beta| 0.15) than for whole blood expression (|Beta| 0.11;
Table 2). For the 2,840 genes that overlapped, the correlation of the betas for the breast tissue
and whole blood analyses was significant (r2 = 0.32; p-value: 2.2x10-16).
We tested for heterogeneity of the associations across studies in the meta-analysis of the
U4C datasets alone, and in the meta-analysis combined with the UK data. These analyses did
not indicate any statistically significant heterogeneity (p-values > 0.10). Furthermore, we did
not detect heterogeneity within ancestry groups (p-values> 0.15), except for ANKLE1 in the
European only meta-analysis (p-value: 0.022). Upon restricting the analysis to women with ER
negative breast cancer, however, we no longer found significant heterogeneity (p-value: 0.32).
Single variants that predict expression and breast cancer risk
Table 2 indicates the number of SNPs identified by PredictDB for optimal prediction of the
genetically regulated expression of each of the genes showing suggestive associations with
breast cancer risk. PrediXcan uses an elastic net method to determine the best set of SNPs for
predicting gene expression. Because elastic net allows for highly correlated variables in predic-
tion models, some of the SNPs are in high linkage disequilibrium (LD). We evaluated associa-
tions between each of the SNPs and breast cancer risk (S2 Table); those achieving nominal (p-
value < 0.05) significance in a meta-analysis of the U4C and UK Biobank data are displayed in
Table 3. The tables also indicate the proportion of total weight attributed to each SNP in the
gene prediction models. The sum of the relative weights for all SNPs contributing to the pre-
diction of any given gene always equals to one, and the SNP ranking remains static. Raw
Cis-eQTLs and breast cancer risk
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weights used for gene expression prediction can be found within the GTEx and DGN Pre-
dictDB databases.
Fig 1 displays the location of eQTL SNPs for the genes for which breast tissue expression
levels were associated with breast cancer risk. The y-axis indicates the strength of association
between the SNPs and breast cancer risk and each point is sized based on the relative contribu-
tion of the variant to gene expression. Among the 24 SNPs predicting expression of RCCD1,
rs3826033 showed the strongest association with breast cancer risk (joint p-value: 9.5x10-06). It
Table 3. SNPs nominally (p-value < 0.05) associated with breast cancer risk that contribute to expression of genes suggestively associated with
breast cancer risk.
Proportion U4C UK Biobank Meta-analysis
SNP Allelesa of Weightb EAFc OR (95% CI) p-value EAFc OR (95% CI) p-value OR (95% CI) p-value
RCCD1 at 15q26.1 (Breast Tissue)
rs3826033d G / A 0.13 0.32 0.92 (0.88, 0.98) 4.1x10-03 0.13 0.86 (0.79,0.93) 2.3x10-04 0.90 (0.86,0.94) 9.5x10-06
rs2290202d G / T 0.24 0.3 0.93 (0.89, 0.98) 5.3x10-03 0.13 0.86 (0.79,0.93) 1.9x10-04 0.91 (0.88,0.95) 1.7x10-05
rs4347602 A / C 0.025 0.72 0.94 (0.90,0.98) 6.5x10-03 0.77 0.96 (0.90,1.02) 0.16 0.94 (0.91,0.98) 2.4x10-03
rs11207d C / T 0.030 0.35 0.97 (0.93, 1.02) 0.21 0.24 0.93 (0.87,0.98) 0.015 0.96 (0.93,0.99) 0.016
DHODH at 16q22.2 (Breast Tissue)
rs3213422 C / A 0.56 0.42 0.92 (0.88,0.96) 2.8x10-05 0.48 0.95 (0.90,1.00) 0.039 0.93 (0.90,0.96) 4.5x10-06
rs2240243 G / A 0.055 0.47 0.93 (0.89,0.97) 2.7x10-04 0.34 0.98 (0.93,1.04) 0.53 0.95 (0.92,0.98) 1.0x10-03
rs12708928 C / A 0.019 0.47 0.93 (0.89,0.96) 2.5x10-04 0.34 0.99 (0.93,1.04) 0.59 0.95 (0.92,0.98) 1.2x10-03
ANKLE1 at 19p13.11 (Breast Tissue)
rs34084277d A / G 0.23 0.19 1.09 (1.02,1.15) 7.1x10-03 0.19 1.11 (1.04,1.18) 2.0x10-03 1.10 (1.05,1.14) 4.7x10-05
rs8170d G / A 0.26 0.19 1.08 (1.02,1.15) 7.2x10-03 0.19 1.11 (1.04,1.18) 2.6x10-03 1.09 (1.05,1.14) 6.3x10-05
RCCD1 at 15q26.1 (Whole Blood)
rs3826033d G / A 0.33 0.32 0.92 (0.88,0.98) 4.1x10-03 0.13 0.86 (0.79,0.93) 2.3x10-04 0.90 (0.86,0.94) 9.5x10-06
rs2290202d G / T 0.29 0.3 0.93 (0.89,0.98) 5.3x10-03 0.13 0.86 (0.79,0.93) 1.9x10-04 0.91 (0.88,0.95) 1.7x10-05
rs7180016d G / A 0.012 0.49 0.97 (0.93,1.01) 0.13 0.16 0.90 (0.84,0.97) 5.7x10-03 0.95 (0.92,0.99) 7.3x10-03
rs11073961 A / G 0.049 0.35 0.97 (0.93,1.01) 0.21 0.27 0.92 (0.87,0.98) 7.5x10-03 0.95 (0.93,0.99) 9.9x10-03
rs11207d C / T 0.0092 0.35 0.97 (0.93,1.02) 0.21 0.24 0.93 (0.87,0.98) 0.015 0.96 (0.93,0.99) 0.016
rs2285937d A / G 0.0064 0.46 0.98 (0.94,1.02) 0.31 0.16 0.90 (0.84,0.97) 4.9x10-03 0.96 (0.93,0.99) 0.023
rs3809583 A / G 0.0035 0.36 0.97 (0.93,1.01) 0.12 0.32 0.96 (0.91,1.01) 0.15 0.96 (0.93,1.00) 0.035
ACAP1 at 17p13.1 (Whole Blood)
rs35776863 A / G 0.49 0.85 1.08 (1.00,1.16) 0.045 0.77 1.11 (1.04,1.18) 0.15 1.10 (1.04,1.15) 1.4x10-04
rs9892383 C / T 0.030 0.76 1.04 (0.98,1.09) 0.17 0.73 1.10 (1.03,1.18) 0.76 1.06 (1.02,1.11) 3.6x10-03
rs5412 G / A 0.060 0.12 1.04 (0.97,1.12) 0.26 0.17 1.09 (1.02,1.17) 0.12 1.07 (1.02,1.12) 8.0x10-03
rs4791423 A / C 0.0068 0.45 1.04 (1.00,1.09) 0.033 0.34 1.03 (0.98,1.09) 0.55 1.04 (1.01,1.08) 0.018
rs35721044 T / C 0.031 0.84 1.11 (1.02,1.22) 0.012 0.76 1.03 (0.97,1.10) 0.16 1.06 (1.01,1.12) 0.019
LRRC25 at 19p13.11 (Whole Blood)
rs11668719 C / T 0.25 0.5 1.06 (1.01,1.11) 0.011 0.54 1.10 (1.05,1.16) 1.87x10-04 1.08 (1.04,1.12) 1.2x10-05
rs7257932d A / G 0.091 0.55 1.05 (1.01,1.10) 0.011 0.67 1.08 (1.02,1.14) 7.01x10-03 1.06 (1.03,1.10) 2.5x10-04
rs13344313 A / G 0.16 0.68 1.06 (1.02,1.11) 6.6x10-03 0.71 1.04 (0.98,1.10) 0.20 1.05 (1.02,1.09) 3.2x10-03
rs3795026 C / T <0.001 0.54 1.04 (1.00,1.08) 0.051 0.68 1.05 (0.99,1.11) 0.12 1.04 (1.01,1.08) 0.013
rs7251067 A / G 0.031 0.85 1.00 (0.95,1.06) 0.94 0.86 1.14 (1.06,1.23) 6.70x10-04 1.05 (1.00,1.10) 0.041
Abbreviations: CI: confidence interval; EAF: effect allele frequency; OR: odds ratio; SNP: single nucleotide polymorphism; U4C: Up for a Challenge
a Reference allele / effect allele
b Proportion of total weight attributed to SNP in gene prediction model
c Effect allele frequency in controls
d Previously implicated in breast cancer or in high linkage disequilibrium (r2 > 0.5 in 1000 Genomes Phase 3 populations) with known risk variants
https://doi.org/10.1371/journal.pgen.1006690.t003
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contributed 13% of the weight for predicting RCCD1 expression, third only to rs2290202
(24%) and rs17821347 (16%). rs2290202 was also strongly associated with breast cancer risk
(p-value: 1.7x10-05). It should be noted that rs3826033 and rs2290202 are in high LD (r2 = 0.97
in 1000 Genomes Phase 3 European populations), and both SNPs are within close proximity
of RCCD1 relative to the other eQTL SNPs. In contrast, rs17821347 is furthest away from
RCCD1 among SNPs predicting RCCD1 expression and showed no evidence of an association
with breast cancer risk (p-value: 0.89). Among the remaining RCCD1 eQTLs, only rs4347602
showed a nominal association (p-value: 2.4x10-03); it has not previously been identified by
GWAS.
All three nominal associations that we identified for SNPs predicting DHODH expression
in breast tissue have not been implicated by GWAS. rs3213422 showed the strongest signal (p-
value: 4.5x10-06) and also contributed the majority of the weight (56%) among the seven SNPs
predicting of DHODH expression. Both rs2240243 and rs12708928 (r2 = 1.0) are in moderate
LD with rs3213422 (r2 = 0.50 for both variants) and also showed evidence of associations with
breast cancer risk (p-values: 1.0x10-03 and 1.3x10-03 respectively). After rs3213422, the second
most weight was contributed by rs7190257 (16%), which showed no evidence of association
(p-value: 0.77).
We identified two SNPs out of six total eQTL SNPs predicting ANKLE1 expression in breast
tissue that were associated with breast cancer; both have been previously associated with breast
cancer risk [14–19]. The SNPs, rs34084277 (p-value: 4.7x10-05) and rs8170 (p-value: 6.3x10-05),
are in perfect LD (r2 = 1.0) and both contributed substantial weight to the prediction of
ANKLE1 expression (23% and 26% respectively). Notably, rs3745162 also contributed substan-
tial weight (24%), but showed no evidence of an association with breast cancer risk (p-value:
0.32).
Fig 2 depicts the genes for which whole blood expression levels were associated with breast
cancer risk. Among the 20 RCCD1 eQTL SNPs, rs3826033 (p-value: 4.1x10-03) and rs2290202
(p-value: 5.3x10-03) contributed the most weight to prediction (33% and 29% respectively)
and were the most strongly associated with breast cancer risk. The other SNPs showing evi-
dence of an association were rs7180016 (p-value: 7.3x10-03), rs11073961 (p-value: 9.9x10-03),
rs11207 (p-value: 0.016), rs2285937 (p-value: 0.023), and rs3809583 (p-value: 0.035). rs3826033,
rs2290202, and rs11207 were included in the both the breast tissue and the whole blood predic-
tion models for RCCD1 expression. Only rs11073961 and rs3809583 have not been previously
implicated in breast cancer GWAS.
Among the 19 ACAP1 whole blood eQTL SNPs, five were nominally associated with breast
cancer risk. Most noteworthy was rs35776863, which not only had the strongest association
with breast cancer risk (p-value: 1.4x10-04), but also contributed nearly half of the weight for
predicting ACAP1 expression (49%). The other SNPs showing evidence of an association were
rs9892383 (p-value: 3.6x10-03), rs5412 (p-value: 8.0x10-03), rs4791423 (p-value: 0.018), and
rs35721044 (p-value: 0.019). None of these SNPs have been previously implicated in breast
cancer GWAS.
Out of 33 LRRC25whole blood eQTL SNPs, five showed evidence of an association with
breast cancer risk. Again, the SNP that contributed the most weight (25%), rs11668719, also
showed the strongest association signal with disease risk (p-value: 1.2x10-05). The next two
Fig 1. LocusZoom plots of SNPs contributing to the breast tissue expression of (A) RCCD1 at 15q26.1, (B)
DHODH at 16q22.2, and (C) ANKLE1 at 19p13.11. The x-axis displays the location of the modeled eQTL
SNPs relative to the genes of interest discovered in analyses breast tissue expression. The y-axis indicates
the strength of association between the SNPs and breast cancer risk. Each point is sized based on the relative
contribution of the variant to gene expression.
https://doi.org/10.1371/journal.pgen.1006690.g001
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strongest signals were for SNPs in moderate LD with rs11668719, namely rs7257932 (r2 = 0.39;
p-value: 2.5x10-04), which is the only SNP predicting LRRC25 expression previously implicated
in breast cancer GWAS, and rs13344313 (r2 = 0.43; p-value: 3.2x10-03). Also suggestively asso-
ciated with breast cancer risk, albeit contributing less than 0.1% of the weight for predicting
LRRC25 expression, was rs3795026 (p-value: 0.013). The last SNP nominally associated with
breast cancer risk was rs7251067 (p-value: 0.041).
Discussion
In this transcriptome-wide association study, we identified five genes for which genetically reg-
ulated expression levels may be associated with breast cancer risk. We also found 23 unique
SNPs contributing to the expression levels of these five genes that were associated with disease.
Out of the 23 SNPs, seven in breast cancer genes identified by GWAS and one in a breast can-
cer gene previously unidentified by GWAS have been previously implicated in breast cancer
or are in high LD (r2 > 0.50 in 1000 Genomes Phase 3 populations) with known risk variants.
The remaining SNPs have not been previously associated with breast cancer risk.
We found that lower predicted expression of RCCD1 (i.e., RCC1 domain containing 1) in
both breast tissue and whole blood was associated with increased breast cancer risk. This find-
ing supports limited existing evidence for the role of RCCD1 in breast cancer. A 2014 GWAS
of East Asian women reported a genome-wide significant association for rs2290203, which is
5,712 bp downstream of RCCD1 on 15q26.1 [20]. The authors then replicated the association
in a European population. They also showed a correlation between rs2290203 and expression
of RCCD1 [20], which supported a previous eQTL analysis of human monocytes that indicated
that rs2290203 is a cis-eQTL for RCCD1 [21]. A more recent study identified an association
between rs8037137, another 15q26.1 SNP in moderate LD with rs2290203 (r2 = 0.59 in 1000
Genomes Phase 3 European populations), and both breast and ovarian cancer [7]. The effect
alleles of both rs2290203 and rs8037137 decrease RCCD1 expression [7,20], aligning with our
finding that lower RCCD1 expression is associated with increased breast cancer risk. Neither
rs2290203 nor rs8037137 was among the SNPs included in PredictDB for the prediction of
RCCD1 expression. However, these SNPs are in LD with RCCD1 eQTL SNPs that were
included in the prediction models, namely rs2290202 (r2 = 0.59 for rs2290203, r2 = 0.99 for
rs8037137) and rs3826033 (r2 = 0.57, r2 = 0.96). The PrediXcan breast tissue model explains
approximately 30% of the variance in RCCD1 expression, and rs2290202 and rs3826033
account for approximately 37% of that variation. The histone demethylase complex formed by
RCCD1 protein with KDM8 is important for chromosomal stability and fidelity during mitosis
division [22]. It is thus plausible that lower expression of RCCD1 could lead to errors in cell
division that could potentially increase the risk of breast cancer. Future studies should evaluate
the specific mechanisms whereby reduced RCCD1 expression could be associated with breast
cancer risk.
ANKLE1 (i.e., ankyrin repeat and LEM domain containing 1) has been previously impli-
cated in breast cancer. Both cis-eQTLs for ANKLE1, rs8170 and rs34084277, among several
other SNPs in the 19p13.11 region, have been identified as breast cancer risk variants in several
GWAS[8,14–19,23–25]. Little experimental evidence exists regarding associations between
over- or under-expression of ANKLE1 and cancer risk. In our study, we found that higher
Fig 2. LocusZoom plots of SNPs contributing to the whole blood expression of (A) RCCD1 at 15q26.1, (B)
ACAP1 at 17p13.1, and (C) LRRC25 at 19p13.11. The x-axis displays the location of the modeled eQTL
SNPs relative to the genes of interest discovered in analyses of whole blood expression. The y-axis indicates
the strength of association between the SNPs and breast cancer risk. Each point is sized based on the relative
contribution of the variant to gene expression.
https://doi.org/10.1371/journal.pgen.1006690.g002
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expression levels of ANKLE1were associated with an increased risk of breast cancer. Variants
in the two SNPs positively associated with ANKLE1 expression in our study were also posi-
tively associated with breast cancer risk in previous work by Antoniou et al. [14]. With regard
to the genotypic association with breast cancer risk, the effect estimates corresponding to
the same risk allele were similar. Specifically, for rs8170, the A allele was positively associated
with breast cancer in the previous study (OR = 1.28 among BRCA1 carriers) and our study
(OR = 1.08). Although the direction of effect was not previously reported for rs34084277, this
variant is in almost perfect LD with rs8170 and shares the same direction of effect in our study
(OR = 1.09). ANKLE1 is an endonuclease involved in DNA damage repair pathways [26]. Its
overexpression could therefore perturb the delicate balance required for DNA damage repair.
That SNPs in the 19p13.11 locus have also been implicated in ovarian cancer [27,28] implies
that ANKLE1may also be involved in hormonally-mediated carcinogenic pathways.
To the best of our knowledge, DHODH, ACAP1, and LRRC25 have not been implicated in
GWAS of breast cancer risk. Even though the imputation quality of DHODH (i.e., dihydrooro-
tate dehydrogenase [quinone]), was lowest among the genes of interest in our study, we still
identified a statistically significant association between decreased expression levels of DHODH
in breast tissue and breast cancer risk. The existing literature regarding the directionality of
association for DHODH and breast cancer is potentially inconsistent; deletion of the 16q22.2
locus has been associated with both better prognosis [29] and increased risk of metastasis [30].
Still, DHODH inhibition has been leveraged in the treatment of breast cancer. In particular, a
DHODH inhibitor called brequinar has been shown to have modest activity in patients with
advanced breast cancer [31]. It is thus difficult to reconcile our findings regarding disease risk
with those of existing studies of disease progression.
ACAP1 (i.e., ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) has not been
implicated in breast cancer risk, but it has been shown to potentially play a role in disease pro-
gression. Its protein product activates the Arf6 protein [32], the expression of which has been
shown to be higher in highly invasive breast cancer than in weakly invasive or noninvasive
breast cancer and normal mammary epithelial cells [33]. ACAP1 also interacts with the third
cytoplasmic loop of SLC2A4/GLUT4. SLC2A4 encodes a protein that functions as an insulin-
regulated facilitative glucose transporter; inhibition of this gene affects cell proliferation and
cell viability, suggesting a potential biological hypothesis for how ACAP1 may be involved with
breast cancer [34].
LRRC25 (i.e., leucine rich repeat containing 25) is more than one megabase away from
ANKLE1 at 19p13.11. It is located in a leukocyte-receptor cluster and may be involved in the
activation of hematopoietic cells, which play a critical role in innate and acquired immunity
[35]. If LRRC25 overexpression results in an elevated inflammatory response, then it could
also increase the risk of breast cancer. In a study of the cis-eQTL activity of known cancer loci,
the 19p13.11 breast cancer risk SNP rs4808801 was most significantly associated with the
expression of LRRC25 (p-value: 3.2 x 10-03) [36]. rs4808801 is in high LD (r2 = 0.88 in 1000
Genomes Phase 3 European populations) with the eQTL rs7257932 that we used to impute
LRRC25.
It is our understanding that ours is the first study to use PrediXcan to impute eQTLs tran-
scriptome-wide toward evaluating associations with cancer. It is important, however, that it be
interpreted in the context of some limitations. The weights housed in PredictDB were largely
developed based on Caucasian samples. However, no SNPs that were monomorphic in any of
the 14 U4C ancestral populations were included in our analysis. Still, whether or not the
weights are valid for application in non-Caucasian populations is unclear and requires further
study. Furthermore, true gene expression was unmeasured. Rather, our study evaluated esti-
mated genetically regulated gene expression, sometimes with low imputation quality. The
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mean expected correlation of imputed genetically regulated gene expression and true gene
expression is 0.097 for breast tissue and 0.145 for whole blood. For most genes, we would not
expect the correlation to approach one given that gene expression is regulated by factors other
than germline genetics, but because PrediXcan was only recently developed, an appropriate
threshold for usable imputation quality is not yet definitive. In the release of PredictDB used
here (dated 8/18/16), the authors only included genes that had a false discovery rate 5%
based on the elastic net models used to generate the SNP weights. With respect to our results,
imputation quality seemed related to the number of SNPs included in the gene expression pre-
diction model. It is interesting, however, that we were still able to detect signal for the genes in
our study for which expression was predicted by the smallest number of SNPs (ANKLE1 and
DHODH). The imputation quality and included genes will likely change as updated versions of
PrediXcan and PredictDB become available. How sensitive findings are to PrediXcan updates
is an important consideration given that prediction is dependent on the reference panel.
In summary, by employing a transcriptome-wide approach, we identified novel associations
for gene expression with breast cancer risk that have not surfaced from traditional GWAS
designs. The approach also allowed for the development of new hypotheses regarding biologi-
cal mechanisms at play in breast carcinogenesis. Future research focusing on the downstream
effects of imputed gene expression, such as gene-gene interactions and gene co-expression net-
works, may further advance the characterization of breast cancer etiology.
Materials and methods
Study populations and genotyping
Discovery analyses used all seven dbGaP datasets provided for the purposes of U4C: African
American Breast Cancer GWAS (AABC); African Diaspora; CGEMS [37,38]; BPC3 [19,39];
San Francisco Bay Area Latina Breast Cancer Study (Latina Admixture); MEC; and Shang-
hai Breast Cancer Genetics Study (Shanghai). All of the U4C datasets provided case-control
status, age, and principal components of race/ethnicity. Genotyping platforms varied by study
as outlined in Table 1. Imputed genotypic data were also made available for U4C, but we
elected to impute each dataset to the same reference panel as described later on.
We used the publicly available UK Biobank as a replication population. The UK Biobank is
a cohort of 500,000 persons aged 40 to 69 recruited from across the United Kingdom between
2006 and 2010. Its protocol has been previously described [13]. In brief, every participant was
evaluated at baseline in-person visits during which assessment center staff introduced a touch-
screen questionnaire, conducted a brief interview, gathered physical measurements, and col-
lected both blood and urine samples.
In an interim data release, UK Biobank has made typed genotypic data available for 152,736
individuals whose blood samples passed QC. Affymetrix genotyped 102,754 of these individuals’
samples with the UK Biobank Axiom array [40] and 49,982 with the UK BiLEVE array [41]. The
former array is an updated version of the latter; it includes additional novel markers that replace
a small fraction of the markers used for genome-wide coverage. In all, the two arrays share over
95% of their marker content, and 806,466 SNPs that passed QC in at least one batch [41].
In addition to the typed data, UK Biobank has released imputed data for 152,249 samples
that were not identified as outliers. Imputation was conducted based on a consolidation of the
UK10K haplotype and the 1000 Genomes Phase 3 reference panels [42]. It resulted in a dataset
of 73,355,667 SNPs, short indels, and large structural variants.
From among the individuals in the UK Biobank with imputed data available, we identified
3,370 European ancestry women diagnosed with breast cancer according to ICD-9 (174) and
ICD-10 (C50) codes. Because non-breast cancers are unlikely to metastasize to breast tissue
Cis-eQTLs and breast cancer risk
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[43], we assumed that all first diagnoses of cancers in the breast were primary malignancies
and included women with prior non-breast cancer diagnoses. Of the 3,370 breast cancers
included in the analysis, 171 (5.1%) had a previous diagnosis of a separate cancer-related con-
dition. A majority of these were nonmelanoma skin cancers (n = 43) or in situ conditions
(n = 50); the number of cases with other malignancies was very low (n = 78, 2.3% of total
cases), and including them was thus unlikely to materially alter our findings. We defined Euro-
pean ancestry individuals as those classified as British, Irish, or any other European back-
ground according to the baseline questionnaire.
We randomly selected 19,717 controls frequency-matched to cases by five-year age groups
from among European ancestry females in the UK Biobank cohort without an ICD9 or ICD10
code for any primary or secondary diagnosis of cancer and with imputed genotypic data.
We excluded from controls any women with a previous cancer to limit the potential for
bias arising from a shared genetic basis underlying different cancers. Age at the time of initial
assessment was calculated by subtracting year of birth from year of assessment; month and day
of birth were unavailable.
Ethics statement
The Institutional Review Boards of each project that made the data used here publicly available
approved the research. Since these are non-identifiable data, we are exempt from Institutional
Review Board approval at our home institution.
Removing duplicates and closely related individuals
For each of the seven U4C datasets and the UK Biobank case-control sub-study, we used the
KING toolset to calculate pairwise kinship coefficients and remove subjects with up to second
degree familial relationships. We found that all participants of the NHS1 were included in
both the CGEMS and BPC3 U4C datasets. We thus excluded the NHS1 from the latter dataset.
For related individuals, we retained one individual from the relationship pair for potential
inclusion in our analyses.
Quality control and imputation
As a first QC step for the U4C datasets, we merged all dbGaP consent groups within each of
the seven studies and then checked self-reported sex against genotypic data (i.e., the X chro-
mosome). We excluded all individuals with sex discrepancies as well as any individuals with
overall call rates < 0.95. Next, we evaluated the rate of heterozygosity for all subjects. Of the
seven U4C datasets, some included data from multiple sub-populations or cohorts (i.e., BPC3,
MEC, and African Diaspora). As a result, we split BPC3, having already excluded the NHS1,
into six datasets (Cancer Prevention Study II [CPSII], European Prospective Investigation into
Cancer and Nutrition [EPIC], MEC—European, Nurses’ Health Study 2 (NHS2), Polish Breast
Cancer Study [PBCS], and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
[PLCO]), MEC into two datasets (MEC—Japanese and MEC—Latina), and African Diaspora
into two datasets (African and African American / Barbadian). Within the four datasets that
we did not split, and in each of the ten newly created split datasets (14 datasets total), we
excluded individuals with a heterozygosity rate greater than three standard deviations from
the mean rate. Regarding SNP QC, we excluded those with an array genotyping rate< 0.98 in
each study, as well as those with a minor allele frequency < 0.02.
Our next step was to ensure that all 14 datasets mapped to the same human reference
genome (hg19). We used liftOver to lift datasets mapped to hg18 over to hg19 as necessary.
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We then ran SHAPEIT for haplotype phasing of each dataset. Finally, we imputed all datasets
to the Haplotype Reference Consortium using Minimac3 [44].
Before being made available, UK Biobank data had already undergone extensive individual-
and SNP-level QC procedures as previously described [13]. We thus used the data as provided
except as outlined in the section below. We also used the imputed data provided by UK Bio-
bank as described in the Study Populations and Genotyping section above.
Principal component analyses
We implemented principal component analysis to assess genetic ancestry in each of the 14
U4C datasets and in the UK Biobank case-control sub-study of unrelated individuals. To do
so, we first LD pruned typed SNPs with r2 > 0.2 in PLINK. Then we excluded SNPs with >
0.2% missingness in the U4C datasets and> 1% missingness in the UK Biobank dataset. With
the remaining data, we determined the principal components (PC) using EIGENSTRAT
within smartpca [45].
Based on the PCs for the U4C datasets, we excluded any individuals outside six standard
deviations along any one of the top ten principal components (S3 Table). For the UK Biobank
dataset, we first focused on the top two PCs to identify any clusters of individuals that may
have comprised separate sub-populations. Upon identifying one such cluster, we excluded out-
liers with a PC eigenvector value greater than seven standard deviations from the mean; doing
so excluded individuals in the identified cluster (S3 Table).
Statistical analyses
Details of the PrediXcan method have been previously described [9]. In brief, PrediXcan uses
reference datasets in which both genomic variation and gene expression levels have been mea-
sured to train additive models of gene expression. The models are constrained using an elastic
net method that allows for the inclusion of highly correlated variables. Estimates from the best
fit models are stored in the publicly available database PredictDB. The application of PrediX-
can to GWAS datasets entails imputing gene expression across the transcriptome using the
weights stored in PredictDB and correlating transcript levels with the phenotype of interest.
For these analyses, we accessed the sets of imputation weights referencing the breast tissue
transcriptome from the GTEx Project and the set of weights referencing the whole blood tran-
scriptome from the Depression Genes Network(DGN) [46,47]. The versions of PrediXcan and
PredictDB used here were dated 6/29/16 and 8/18/16, respectively. We used each set of weights
to impute the transcriptome in each of our 14 discovery datasets and in our replication dataset
based on the subset of SNPs with imputation quality 0.3. In each dataset, we performed
logistic regression to estimate the associations between imputed transcript levels and breast
cancer risk, adjusted for the top ten PCs and age. Finally, we combined the results from the 14
discovery datasets and then included the replication dataset using inverse-variance-weighted
fixed-effects meta-analyses. We assessed heterogeneity in the meta-analyses of the discovery
U4C datasets, and in the joint meta-analyses with the UK data using Cochran’s Q-test as
implemented by METAL [48].
When a joint meta-analysis indicated a suggestive association between expression of a par-
ticular gene and breast cancer risk, we evaluated associations between its cis-eQTLs and breast
cancer risk. Again, we performed logistic regression adjusted for the top ten PCs and age in
each dataset and then combined estimates via meta-analysis.
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 14 / 19
Supporting information
S1 Table. Effect estimates and standard errors for associations nominally (p-value< 0.05) sig-
nificant in a meta-analysis of the discovery Up for a Challenge datasets between breast cancer
risk and the imputed expression of genes based on (A) breast tissue and (B) whole blood.
(PDF)
S2 Table. Association of breast cancer risk with SNPs that contribute to the expression of (A)
RCCD1 in breast tissue, (B) DHODH in breast tissue, (C) ANKLE1 in breast tissue, (D) RCCD1
in whole blood, (E) ACAP1 in whole blood, and (F) LRRC25 in whole blood.
(PDF)
S3 Table. Number of subjects removed from each cohort because of outlier principal compo-
nents.
(PDF)
S1 Fig. Forest plots of PrediXcan results for breast tissue expression of (A) RCCD1, (B)
DHODH, and (C) ANKLE1.
(PDF)
S2 Fig. Forest plots of PrediXcan results for whole blood expression of (A) RCCD1, (B)
ACAP1, and (C) LRRC25.
(PDF)
S3 Fig. Volcano plots of PrediXcan results for associations between breast cancer risk and the
imputed expression of (A) 4,469 genes based on breast tissue and (B) 9,768 genes based on
whole blood (genes with beta estimates outside three standard deviations from the mean were
removed from the plots– 4 for breast tissue and 23 for whole blood).
(PDF)
Acknowledgments
We thank the organizers and judges of the U4C for the foresight and effort to create and lead
the challenge. We especially thank Drs. Leah Mechanic, Elizabeth Gillanders, Sara Lindstro¨m,
and Kenneth Dailey. We also thank the below seven U4C breast cancer studies for making
their data available. In addition, this research was conducted using the UK Biobank Resource
(#14105).
San Francisco Bay Area Latina Breast Cancer Study (dbGaP Study Accession
phs000912.v1.p1). Study investigators include Elad Ziv and Esther M. John. Genotyping for
this study was supported by a grant from NIH (R01 CA120120 to E. Ziv). Sample collection
was supported in part by Department of Defense Breast Cancer Research Program (BC030551
to E. Ziv). Additional support was provided by NIH (K24CA169004). The SFBCS was sup-
ported by grants to E. John from NIH (R01 CA063446 and R01 CA077305), Department of
Defense Breast Cancer Research Program (DAMD17-96-1-6071), and the California Breast
Cancer Research Program (7PB-0068). The Northern California site of the Breast Cancer Fam-
ily Registry (BCFR) was supported by NIH (U01 CA069417 and UM1 CA164920).
African American Breast Cancer GWAS (dbGaP Study Accession phs000851.v1.p1).
Study investigators include: Christine Ambrosone, Leslie Bernstein, Chris Haiman, Jennifer
Hu, Esther John, Andy Olshan, Wei Zheng, and Regina Ziegler. Funding support was by a
Department of Defense Breast Cancer Research Program Era of Hope Scholar Award to C.A.
H. (W81XWH-08-1-0383), the Norris Foundation and U19-CA148065. Each of the participat-
ing studies was supported by the following grants: MEC (National Institutes of Health grants
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 15 / 19
R01-CA63464, R37-CA54281 and UM1-CA164973); CARE (National Institute for Child
Health and Development grant NO1-HD-3-3175, K05 CA136967); WCHS (US Army Medical
Research and Material Command (USAMRMC) grant DAMD-17-01-0-0334, the National
Institutes of Health grant R01-CA100598 and in part by a grant from the Breast Cancer
Research Foundation); CBCS (National Institutes of Health Specialized Program of Research
Excellence in Breast Cancer, grant number P50-CA58223 and Center for Environmental
Health and Susceptibility National Institute of Environmental Health Sciences, National Insti-
tutes of Health, grant number P30-ES10126); PLCO (Intramural Research Program, National
Cancer Institute, National Institutes of Health); NBHS (National Institutes of Health grant
R01-CA100374); WFBC (National Institutes of Health grant R01-CA73629). The Breast Can-
cer Family Registry (BCFR) was supported by grant UM1 CA164920 from the National Cancer
Institute.
The Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of Aggressive Pros-
tate Cancer and ER- Breast Cancer (dbGaP Study Accession: phs000812.v1.p1).
The Breast and Prostate Cancer Cohort Consortium (BPC3) genome-wide association stud-
ies of advanced prostate cancer and estrogen-receptor negative breast cancer was supported by
the National Cancer Institute under cooperative agreements U01-CA98233, U01-CA98710,
U01-CA98216, and U01-CA98758 and the Intramural Research Program of the National Can-
cer Institute, Division of Cancer Epidemiology and Genetics.
Cancer Genetic Markers of Susceptibility (CGEMS) Breast Cancer Genome-wide Asso-
ciation Study (GWAS)—Primary Scan: Nurses’ Health Study—Additional Cases: Nurses’
Health Study 2 (dbGaP Study Accession: phs000147.v3.p1)
GWAS in African Americans, Latinos and Japanese (dbGaP Study Accession:
phs000517.v3.p1). Multiethnic Cohort and the genotyping in this study were funded by grants
from the National Institute of Health (CA63464, CA54281, CA098758, CA132839 and
HG005922) and the Department of Defense Breast Cancer Research Program (W81XWH-08-
1-0383).
Genome-Wide Association Study of Breast Cancer in the African Diaspora—the ROOT
study (dbGaP Study Accession: phs000383.v1.p1). The GWAS of Breast Cancer in the Afri-
can Diaspora is conducted by the University of Chicago and supported by the National Cancer
Institute (R01 CA142996-02). This manuscript was not prepared in collaboration with investi-
gators of the GWAS of Breast Cancer in the African Diaspora and does not necessarily reflect
the opinions or views of the University of Chicago, or NCI.
Shanghai Breast Cancer Genetics Study (SBCGS) (dbGaP Study Accession: phs000799.
v1.p1). We acknowledge the Shanghai Breast Cancer Study (R01CA64277) and Shanghai
Women’s Health Study (R37CA70867) that generated these data.
The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Author Contributions
Conceptualization: JDH REG NZ EZ JSW.
Data curation: JDH REG LL.
Formal analysis: JDH REG NCE CGT MNP DH SH AM.
Funding acquisition: JSW.
Investigation: JDH REG LL.
Methodology: DH.
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 16 / 19
Project administration: JDH REG JSW.
Software: JDH REG NCE DH SH.
Supervision: JSW.
Validation: JDH REG DH.
Visualization: JDH REG NCE CGT MNP.
Writing – original draft: JDH REG JSW.
Writing – review & editing: JDH REG NCE CGT EZ JSW.
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International
Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 09/19/2016.
2. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies
including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;
358(9291):1389–99. https://doi.org/10.1016/S0140-6736(01)06524-2 PMID: 11705483
3. Kharazmi E, Chen T, Narod S, Sundquist K, Hemminki K. Effect of multiplicity, laterality, and age at
onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study. Breast
Cancer Res Treat. 2014; 144(1):185–92. https://doi.org/10.1007/s10549-014-2848-3 PMID: 24487690
4. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a
systematic review and meta-analysis. Int J Cancer. 1997; 71(5):800–9. PMID: 9180149
5. Moller S, Mucci LA, Harris JR, Scheike T, Holst K, Halekoh U, et al. The heritability of breast cancer
among women in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 25
(1):145–50. https://doi.org/10.1158/1055-9965.EPI-15-0913 PMID: 26554920
6. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk:
comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;
12(5):477–88. https://doi.org/10.1016/S1470-2045(11)70076-6 PMID: 21514219
7. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, et al. Genome-wide meta-
analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility
loci shared by at least two cancer types. Cancer Discov. 2016; 6(9):1052–67. https://doi.org/10.1158/
2159-8290.CD-15-1227 PMID: 27432226
8. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association
analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat
Genet. 2015; 47(4):373–80. https://doi.org/10.1038/ng.3242 PMID: 25751625
9. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene-
based association method for mapping traits using reference transcriptome data. Nat Genet. 2015; 47
(9):1091–8. https://doi.org/10.1038/ng.3367 PMID: 26258848
10. Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritabil-
ity of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture.
PLoS Genet. 2013; 9(10):e1003864. https://doi.org/10.1371/journal.pgen.1003864 PMID: 24204291
11. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs
are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A. 2010; 107(20):9287–92.
https://doi.org/10.1073/pnas.1001827107 PMID: 20442332
12. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely
to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010; 6(4):e1000888. https://
doi.org/10.1371/journal.pgen.1000888 PMID: 20369019
13. UK Biobank: Protocol for a large-scale prospective epidemiological resource [Internet]. UK Biobank
Coordinating Centre 2007. Available from: http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/
UK-Biobank-Protocol.pdf?phpMyAdmin=trmKQlYdjjnQIgJ%2CfAzikMhEnx6, accessed on 02/22/2016.
14. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13
modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-neg-
ative breast cancer in the general population. Nat Genet. 2010; 42(10):885–92. https://doi.org/10.1038/
ng.669 PMID: 20852631
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 17 / 19
15. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, et al. Identifi-
cation of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun.
2016; 7:11375. https://doi.org/10.1038/ncomms11375 PMID: 27117709
16. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, et al. Genome-wide associa-
tion study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer
risk. PLoS Genet. 2013; 9(3):e1003212. https://doi.org/10.1371/journal.pgen.1003212 PMID:
23544013
17. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide
association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013; 45
(4):392–8, 8e1-2. https://doi.org/10.1038/ng.2561 PMID: 23535733
18. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, et al. Associ-
ations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and
BRCA2 mutation carriers. Breast Cancer Res. 2014; 16(6):3416. https://doi.org/10.1186/s13058-014-
0492-9 PMID: 25919761
19. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, et al. A meta-analysis of genome-
wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.
Hum Mol Genet. 2012; 21(24):5373–84. https://doi.org/10.1093/hmg/dds381 PMID: 22976474
20. Cai Q, Zhang B, Sung H, Low SK, Kweon SS, Lu W, et al. Genome-wide association analysis in East
Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014; 46
(8):886–90. https://doi.org/10.1038/ng.3041 PMID: 25038754
21. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and beyond—the tran-
scriptome of human monocytes and disease susceptibility. PLoS One. 2010; 5(5):e10693. https://doi.
org/10.1371/journal.pone.0010693 PMID: 20502693
22. Marcon E, Ni Z, Pu S, Turinsky AL, Trimble SS, Olsen JB, et al. Human-chromatin-related protein inter-
actions identify a demethylase complex required for chromosome segregation. Cell Rep. 2014; 8
(1):297–310. https://doi.org/10.1016/j.celrep.2014.05.050 PMID: 24981860
23. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyp-
ing identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013; 45(4):353–61, 61e1-2.
https://doi.org/10.1038/ng.2563 PMID: 23535729
24. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal
carcinoma in situ of the breast. Breast Cancer Res. 2016; 18(1):22. https://doi.org/10.1186/s13058-
016-0675-7 PMID: 26884359
25. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, et al. Genome-wide associ-
ation study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast
cancer. Carcinogenesis. 2014; 35(5):1012–9. https://doi.org/10.1093/carcin/bgt404 PMID: 24325915
26. Brachner A, Foisner R. Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biol-
ogy. In: Schirmer EC, de las Heras JI, editors. Cancer Biology and the Nuclear Envelope: Recent
Advances May Elucidate Past Paradoxes. 773. 2014/02/25 ed. New York, NY: Springer New York;
2014. p. 143–63.
27. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are
associated with susceptibility to ovarian cancer. Nat Genet. 2010; 42(10):880–4. https://doi.org/10.
1038/ng.666 PMID: 20852633
28. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis
and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013; 45(4):362–
70, 70e1-2. https://doi.org/10.1038/ng.2564 PMID: 23535730
29. Nordgard SH, Johansen FE, Alnaes GI, Bucher E, Syvanen AC, Naume B, et al. Genome-wide analysis
identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline
haplotypes in breast cancer patients. Genes Chromosomes Cancer. 2008; 47(8):680–96. https://doi.
org/10.1002/gcc.20569 PMID: 18398821
30. Driouch K, Dorion-Bonnet F, Briffod M, Champeme MH, Longy M, Lidereau R. Loss of heterozygosity
on chromosome arm 16q in breast cancer metastases. Genes Chromosomes Cancer. 1997; 19
(3):185–91. PMID: 9219000
31. Cody R, Stewart D, DeForni M, Moore M, Dallaire B, Azarnia N, et al. Multicenter phase II study of bre-
quinar sodium in patients with advanced breast cancer. Am J Clin Oncol. 1993; 16(6):526–8. PMID:
8256771
32. Ha VL, Luo R, Nie Z, Randazzo PA. Contribution of AZAP-Type Arf GAPs to cancer cell migration and
invasion. Adv Cancer Res. 2008; 101:1–28. https://doi.org/10.1016/S0065-230X(08)00401-6 PMID:
19055940
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 18 / 19
33. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A, et al. Requirement for
Arf6 in breast cancer invasive activities. Proc Natl Acad Sci U S A. 2004; 101(17):6647–52. https://doi.
org/10.1073/pnas.0401753101 PMID: 15087504
34. Garrido P, Osorio FG, Moran J, Cabello E, Alonso A, Freije JM, et al. Loss of GLUT4 induces metabolic
reprogramming and impairs viability of breast cancer cells. J Cell Physiol. 2015; 230(1):191–8. https://
doi.org/10.1002/jcp.24698 PMID: 24931902
35. Rissoan MC, Duhen T, Bridon JM, Bendriss-Vermare N, Peronne C, de Saint Vis B, et al. Subtractive
hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3
novel transcripts in human plasmacytoid dendritic cells. Blood. 2002; 100(9):3295–303. https://doi.org/
10.1182/blood-2002-02-0638 PMID: 12384430
36. Li Q, Stram A, Chen C, Kar S, Gayther S, Pharoah P, et al. Expression QTL-based analyses reveal can-
didate causal genes and loci across five tumor types. Hum Mol Genet. 2014; 23(19):5294–302. https://
doi.org/10.1093/hmg/ddu228 PMID: 24907074
37. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al. A common variant at the
TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011;
43(12):1210–4. https://doi.org/10.1038/ng.985 PMID: 22037553
38. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association
study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat
Genet. 2007; 39(7):870–4. https://doi.org/10.1038/ng2075 PMID: 17529973
39. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-wide associa-
tion study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011; 20(19):3867–75.
https://doi.org/10.1093/hmg/ddr295 PMID: 21743057
40. UK Biobank Axiom Array: Content Summary [Internet]. 2014. Available from: http://www.ukbiobank.ac.
uk/wp-content/uploads/2014/04/UK-Biobank-Axiom-Array-Content-Summary-2014.pdf, accessed on
02/22/2016.
41. Genotyping and quality control of UK Biobank, a large-scale, extensively phenotyped prospective
resource [Internet]. 2015. Available from: http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/
UKBiobank_genotyping_QC_documentation-web.pdf, accessed on 02/22/2016.
42. Genotype imputation and genetic association studies of UK Biobank [Internet]. 2015. Available from:
http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/imputation_documentation_May2015.pdf,
accessed on 02/22/2016.
43. Benveniste AP, Marom EM, Benveniste MF, Mawlawi OR, Miranda RN, Yang W. Metastases to the
breast from extramammary malignancies—PET/CT findings. Eur J Radiol. 2014; 83(7):1106–12.
https://doi.org/10.1016/j.ejrad.2014.04.015 PMID: 24844731
44. Michigan Imputation Server [Internet]. Available from: https://imputationserver.sph.umich.edu/index.
html, accessed on 02/23/2016.
45. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analy-
sis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904–9.
https://doi.org/10.1038/ng1847 PMID: 16862161
46. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45(6):580–5. https://doi.org/10.
1038/ng.2653 PMID: 23715323
47. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the genetic
basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res. 2014; 24
(1):14–24. https://doi.org/10.1101/gr.155192.113 PMID: 24092820
48. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
scans. Bioinformatics. 2010; 26(17):2190–1. https://doi.org/10.1093/bioinformatics/btq340 PMID:
20616382
Cis-eQTLs and breast cancer risk
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006690 March 31, 2017 19 / 19
